OPENING BELL: Nifty FUTURE DOWN -2 .00 @ 9507.75,
BANK NIFTY FUTURE up + 0.45 @ 23.033
USDINR @ 64.5150
TBR UPDATE: NIFTY FUTURE: S1-9419.77, S2 9329.43, R1- 9559.17, R2-9608.23
BANK NIFTY FUTURE: S1 – 22729.47, S2-22263.58, R1- 23449.62, R2 23703.88
Cipla falls 5% after weak Q4 results
Shares of drug maker CiplaBSE -2.90 % dropped 5 per cent in Friday’s trade after the company registered a consolidated net loss of 61.79 crore for the quarter ended March 31, 2017 as against net loss of Rs 92.83 in the corresponding quarter last year.
The scrip of the company opened at Rs 480, touched highs and lows of Rs 504.15 and Rs 479, and was trading at Rs 481.45, down 4.5 per cent at 9:31 AM (IST).
The BSE Sensex was trading at 30,834, up 84.54, or 0.27 per cent.
Cipla’s consolidated total revenue increased by 6.84 per cent to Rs 3,604.79 crore in the quarter under review, as against Rs 3,373.91 crore in the corresponding quarter.
For the quarter ended March 31, 2017, the company started commercial production at its newly built formulation facility at Sikkim.
For more updates click here - http://www.tradebizzindia.com/freetrial
BANK NIFTY FUTURE up + 0.45 @ 23.033
USDINR @ 64.5150
TBR UPDATE: NIFTY FUTURE: S1-9419.77, S2 9329.43, R1- 9559.17, R2-9608.23
BANK NIFTY FUTURE: S1 – 22729.47, S2-22263.58, R1- 23449.62, R2 23703.88
Cipla falls 5% after weak Q4 results
Shares of drug maker CiplaBSE -2.90 % dropped 5 per cent in Friday’s trade after the company registered a consolidated net loss of 61.79 crore for the quarter ended March 31, 2017 as against net loss of Rs 92.83 in the corresponding quarter last year.
The scrip of the company opened at Rs 480, touched highs and lows of Rs 504.15 and Rs 479, and was trading at Rs 481.45, down 4.5 per cent at 9:31 AM (IST).
The BSE Sensex was trading at 30,834, up 84.54, or 0.27 per cent.
Cipla’s consolidated total revenue increased by 6.84 per cent to Rs 3,604.79 crore in the quarter under review, as against Rs 3,373.91 crore in the corresponding quarter.
For the quarter ended March 31, 2017, the company started commercial production at its newly built formulation facility at Sikkim.
For more updates click here - http://www.tradebizzindia.com/freetrial
This post first appeared on Stock Market Tips Provider - TradeBizz Research, please read the originial post: here